FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2247377728> ?p ?o ?g. }

• W2247377728 endingPage "19564" @default.
• W2247377728 startingPage "19564" @default.
• W2247377728 abstract "19564 Background: Emerging data suggest that initiating EPO therapy earlier (at a higher hemoglobin [Hb] trigger) in the setting of active CT may provide better maintenance of Hb within a target range with no adverse safety consequence. Reported here are the final results of the first study to explore the efficacy and safety of early vs standard intervention with EPO initiated Q3W at 120,000 U. Methods: This 16-wk open-label randomized study enrolled pts with non-myeloid malignancy, baseline (BL) Hb =11.0 and =12.0 g/dL, and CT planned for =9 wks. Pts were randomized (1:1) to receive EPO 120,000 U subcutaneously Q3W immediately (early intervention group, EIG) or when their Hb fell to <11.0 g/dL (standard intervention group, SIG). If, at any dosing visit after the first EPO dose, Hb decreased to <10.0 g/dL, pts were switched to EPO 40,000 U weekly (QW). Dose was withheld for Hb >13.0 g/dL at any dosing visit; dose was reduced for Hb >12.0 g/dL or Hb increase >1.5 g/dL in a 3-wk period (current prescribing information recommends target Hb not to exceed 12 g/dL). Hb response was defined as Percent Values in Range (PVR; the mean proportion of weekly Hb levels that were =11.0 and =13.0 g/dL) and by mean Hb change from BL. Hb data following switch to 40,000 U QW were censored. Results: A total of 136 pts were randomized (68 per group). Demographics were similar; BL Hb was 11.5 g/dL in both groups. PVR was 60% in the EIG and SIG. Mean Hb change from BL to final value on Q3W dosing was -0.1 g/dL in both groups. Among the 51 pts whose Hb fell below 11 g/dL in the SIG, their Hb decreased to a mean of 10.4 g/dL before initiation of EPO. Their subsequent mean Hb increase was 0.7 g/dL at the final visit on Q3W therapy. PRBC transfusion rates after the first 4 wks of EPO treatment were 8.8% (6/68) and 7.8% (4/51) for the EIG and SIG, respectively. In the EIG vs SIG, EPO was withheld in 38% vs 22% of pts and reduced in 43% vs 26% of pts. Two deaths and 6 clinically relevant TVEs while on EPO treatment were reported in each group. Conclusions: This is the first study to show EPO may be initiated at 120,000 U every 3 wks. Hb outcomes in the EIG and SIG were similar. These data provide further evidence that half-life of erythropoietins may not correlate with their effectiveness when used at extended dosing intervals. Future research is warranted. No significant financial relationships to disclose." @default.
• W2247377728 created "2016-06-24" @default.
• W2247377728 creator A5033199189 @default.
• W2247377728 creator A5033661505 @default.
• W2247377728 creator A5034876741 @default.
• W2247377728 creator A5059232093 @default.
• W2247377728 creator A5080006341 @default.
• W2247377728 date "2007-06-20" @default.
• W2247377728 modified "2023-09-24" @default.
• W2247377728 title "Initiating epoetin alfa (EPO) 120,000 U every three weeks (Q3W) in pts with chemotherapy (CT)-induced anemia (CIA)" @default.
• W2247377728 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.19564" @default.
• W2247377728 hasPublicationYear "2007" @default.
• W2247377728 type Work @default.
• W2247377728 sameAs 2247377728 @default.
• W2247377728 citedByCount "1" @default.
• W2247377728 crossrefType "journal-article" @default.
• W2247377728 hasAuthorship W2247377728A5033199189 @default.
• W2247377728 hasAuthorship W2247377728A5033661505 @default.
• W2247377728 hasAuthorship W2247377728A5034876741 @default.
• W2247377728 hasAuthorship W2247377728A5059232093 @default.
• W2247377728 hasAuthorship W2247377728A5080006341 @default.
• W2247377728 hasConcept C126322002 @default.
• W2247377728 hasConcept C197934379 @default.
• W2247377728 hasConcept C2776164570 @default.
• W2247377728 hasConcept C2777288759 @default.
• W2247377728 hasConcept C2778248108 @default.
• W2247377728 hasConcept C2778917026 @default.
• W2247377728 hasConcept C71924100 @default.
• W2247377728 hasConcept C90924648 @default.
• W2247377728 hasConceptScore W2247377728C126322002 @default.
• W2247377728 hasConceptScore W2247377728C197934379 @default.
• W2247377728 hasConceptScore W2247377728C2776164570 @default.
• W2247377728 hasConceptScore W2247377728C2777288759 @default.
• W2247377728 hasConceptScore W2247377728C2778248108 @default.
• W2247377728 hasConceptScore W2247377728C2778917026 @default.
• W2247377728 hasConceptScore W2247377728C71924100 @default.
• W2247377728 hasConceptScore W2247377728C90924648 @default.
• W2247377728 hasIssue "18_suppl" @default.
• W2247377728 hasLocation W22473777281 @default.
• W2247377728 hasOpenAccess W2247377728 @default.
• W2247377728 hasPrimaryLocation W22473777281 @default.
• W2247377728 hasRelatedWork W1867073577 @default.
• W2247377728 hasRelatedWork W2014074349 @default.
• W2247377728 hasRelatedWork W2016504951 @default.
• W2247377728 hasRelatedWork W2048125117 @default.
• W2247377728 hasRelatedWork W2094875169 @default.
• W2247377728 hasRelatedWork W2096760803 @default.
• W2247377728 hasRelatedWork W2108880404 @default.
• W2247377728 hasRelatedWork W2148520689 @default.
• W2247377728 hasRelatedWork W2559607918 @default.
• W2247377728 hasRelatedWork W2559768387 @default.
• W2247377728 hasVolume "25" @default.
• W2247377728 isParatext "false" @default.
• W2247377728 isRetracted "false" @default.
• W2247377728 magId "2247377728" @default.
• W2247377728 workType "article" @default.